Latest Licensing News

BTC Health has transformed its decade-long license agreement with Arna Pharma into an indefinite partnership, gaining royalties from Singapore and Malaysia sales and first rights to new pharmaceutical products in Australia and New Zealand.

Terramin Australia has lodged an appeal after the Supreme Court dismissed its mining lease application for the Bird in Hand Gold Project, underscoring the project's significant economic and environmental potential for South Australia.

DMC Mining Limited has extended the closing date for its public share offer to May 8, 2025, due to delays in obtaining exploration licenses for its Firawa and Labe Projects in Guinea. The company plans to lodge a second supplementary prospectus to adjust regulatory conditions accordingly.

Neuren Pharmaceuticals has received a significant cash inflow of approximately US$50 million following the sale of a Priority Review Voucher linked to its Rett syndrome treatment. This milestone underscores the growing value of Neuren’s neurological drug portfolio and its partnership with Acadia Pharmaceuticals.

Acrux Limited announces the retirement of CEO Michael Kotsanis after more than 10 years at the helm, with a search underway for his successor to lead the next phase of growth.

Adelong Gold Limited has raised $1.173 million through a placement to fund exploration and development at its NSW gold project and lithium ventures in Brazil. The capital raise, including free attaching options, signals investor confidence as the company advances towards production.

Invex Therapeutics reports a significant reduction in net loss for H1 FY2025 alongside promising pre-clinical data for Exenatide in Alzheimer’s Disease models.

Evion Group has raised $2 million through a Rights Issue and Shortfall Placement to accelerate expansion of its Panthera Graphite JV, aiming to double production capacity amid strong global demand.

PARKD has inked a pivotal five-year exclusive licensing agreement with Fielders, a BlueScope Steel division, to commercialise its innovative MDSB® and MDSS® products in Australia and explore international expansion.

New World Resources has secured a critical federal permitting milestone for its Antler Copper Project, setting a clear path to full approval within 12 months and construction commencement in H2 2025.

AdAlta Limited is accelerating its 'East to West' cellular immunotherapy strategy, aiming to bridge Asian innovation with Western clinical development and manufacturing to target solid cancers. The company plans to secure three assets by the end of 2025 and initiate clinical trials, positioning itself as a leader in this emerging market.

Neuren Pharmaceuticals has secured a pivotal FDA Type C Meeting to discuss primary efficacy endpoints for its Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, advancing its rare disease drug development.